Aptamer-functionalized liposomes for targeted cancer therapy

被引：151
作者：
Moosavian, Seyedeh Alia [1 ]
Sahebkar, Amirhossein [2 ,3 ,4 ]
机构：
[1] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Nanotechnol Res Ctr, Mashhad, Razavi Khorasan, Iran
[2] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Razavi Khorasan, Iran
[3] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, Razavi Khorasan, Iran
[4] Mashhad Univ Med Sci, Sch Pharm, Mashhad, Razavi Khorasan, Iran
来源：
CANCER LETTERS | 2019年 / 448卷
关键词：
Chemotherapy; Drug delivery; Liposome; Aptamer; QUADRUPLEX DNA APTAMERS; GROWTH-FACTOR RECEPTOR; DRUG-DELIVERY SYSTEMS; IN-VITRO SELECTION; PROTEIN CORONA; PHASE-II; OLIGONUCLEOTIDE AS1411; POLYETHYLENE-GLYCOL; TUMOR PENETRATION; EMERGING CLASS;
D O I：
10.1016/j.canlet.2019.01.045
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Accumulation of chemotherapeutic agents in the tumor tissue while reducing adverse effects and drug resistance are among the major goals in cancer therapy. Among nanocarriers, liposomes have been found to be more effective in the passive targeting of cancer cells. A promising recent development in targeted drug delivery is the use of aptamer-functionalized liposomes for cancer therapy. Aptamer-targeted liposomes have enhanced uptake in tumor cells as shown in vitro and in vivo. Here, we discuss the aptamer-functionalized liposome platforms and review functionalization approaches as well as the factors affecting antitumor efficiency of aptamer-targeted liposomal systems. Finally, we provide a comprehensive overview of aptamer-targeted liposomes based on the molecular targets on the surface of cancer cells.
引用
收藏
页码：144 / 154
页数：11
相关论文
共 118 条
[1]   In Vitro Selection of Modified RNA Aptamers Against CD44 Cancer Stem Cell Marker [J].
Ababneh, Nidaa ;
Alshaer, Walhan ;
Allozi, Omar ;
Mahafzah, Azmi ;
El-Khateeb, Mohammed ;
Hillaireau, Herve ;
Noiray, Magali ;
Fattal, Elias ;
Ismail, Said .
NUCLEIC ACID THERAPEUTICS, 2013, 23 (06) :401-407
[2]   Liposomal drug delivery systems: From concept to clinical applications [J].
Allen, Theresa M. ;
Cullis, Pieter R. .
ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) :36-48
[3]   Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates [J].
Allen, TM ;
Mumbengegwi, DR ;
Charrois, GJR .
CLINICAL CANCER RESEARCH, 2005, 11 (09) :3567-3573
[4]  
Allen TM, 2002, CELL MOL BIOL LETT, V7, P889
[5]   Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells [J].
Alshaer, Walhan ;
Hillaireau, Herve ;
Vergnaud, Juliette ;
Ismail, Said ;
Fattal, Elias .
BIOCONJUGATE CHEMISTRY, 2015, 26 (07) :1307-1313
[6]   Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release [J].
Andresen, TL ;
Jensen, SS ;
Jorgensen, K .
PROGRESS IN LIPID RESEARCH, 2005, 44 (01) :68-97
[7]   Nanoparticles in the clinic [J].
Anselmo, Aaron C. ;
Mitragotri, Samir .
BIOENGINEERING & TRANSLATIONAL MEDICINE, 2016, 1 (01) :10-29
[8]   An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells [J].
Ara, Mst Naznin ;
Matsuda, Takashi ;
Hyodo, Mamoru ;
Sakurai, Yu ;
Hatakeyama, Hiroto ;
Ohga, Noritaka ;
Hida, Kyoko ;
Harashima, Hideyoshi .
BIOMATERIALS, 2014, 35 (25) :7110-7120
[9]   Rationally Manipulating Aptamer Binding Affinities in a Stem-Loop Molecular Beacon [J].
Armstrong, Rachel E. ;
Strouse, Geoffrey F. .
BIOCONJUGATE CHEMISTRY, 2014, 25 (10) :1769-1776
[10]   Thrombin Binding Aptamer, More than a Simple Aptamer: Chemically Modified Derivatives and Biomedical Applications [J].
Avino, Anna ;
Fabrega, Carme ;
Tintore, Maria ;
Eritja, Ramon .
CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (14) :2036-2047
12345678910